Abstract
Background MedImmune is the biologics business unit of AstraZeneca with a mission of helping patients with significant unmet medical need by developing innovative medicines. MedImmune has a rich pipeline across five therapeutic areas including oncology, respiratory, inflammatory and autoimmunity, infectious diseases, neurosciences, cardiovascular and gastrointestinal diseases. To realize our vision of personalized healthcare—treating the right patient with the right drug at the right dose, we are applying cutting edge tools such as next-gen sequencing, circulating tumor cells and advanced PK/PD modelling across the pipeline.
Highlights
MedImmune is the biologics business unit of AstraZeneca with a mission of helping patients with significant unmet medical need by developing innovative medicines
To realize our vision of personalized healthcare—treating the right patient with the right drug at the right dose, we are applying cutting edge tools such as next-gen sequencing, circulating tumor cells and advanced PK/PD modelling across the pipeline
MedImmune is committed to helping Chinese patients with significant unmet medical need and we believe collaborations with leading Chinese PIs and innovation are key to our mission
Summary
MedImmune is the biologics business unit of AstraZeneca with a mission of helping patients with significant unmet medical need by developing innovative medicines. From 2012 Sino-American Symposium on Clinical and Translational Medicine (SAS-CTM) Shanghai, China. Background MedImmune is the biologics business unit of AstraZeneca with a mission of helping patients with significant unmet medical need by developing innovative medicines.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.